☆ 4.3 Article

Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial

Fabrice Andre et al.

Summary: In the DESTINY-Breast02 trial, the efficacy and safety of trastuzumab deruxtecan was compared with the treatment of physician's choice in patients with HER2-positive metastatic breast cancer. The results demonstrated that trastuzumab deruxtecan showed significant superiority in progression-free survival compared to other treatment options, and had a favorable benefit-risk profile.

LANCET (2023)

Add to Collection

Article Multidisciplinary Sciences

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Takayuki Yoshino et al.

Summary: This article reports the final results of a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC). The primary analysis showed an objective response rate (ORR) of 45.3% in HER2-positive patients, while no responses were observed in other HER2 statuses. The most common adverse events of T-DXd were decreased neutrophil count and anemia. These findings support further exploration of T-DXd in HER2-positive mCRC.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Pharmacology & Pharmacy

Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis

Kazutaka Yoshihara et al.

Summary: This study assessed the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer. The pharmacokinetics of T-DXd were analyzed using a population pharmacokinetic model, and exposure-efficacy and exposure-safety analyses were conducted. The study found that T-DXd at a dose of 6.4 mg/kg was recommended for HER2-positive gastric cancer, as it demonstrated higher efficacy compared to a dose of 5.4 mg/kg and had comparable exposure and safety profiles.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021

Hideki Maeda et al.

Summary: This study characterized and assessed the compassionate use program's application in Japan by evaluating expanded access clinical trials conducted between 2016 and 2021. It found that out of 2,031 pivotal clinical trials conducted in Japan during the 5-year period, 31 were compassionate use trials, with the majority (77.4%) involving anticancer drugs and a small portion (16.1%) conducted in children. Additionally, only 11.2% of trials with high social and patient demands implemented the compassionate use program. The average time from the start of the program to new drug application submission and approval was 9.0 days and 208.0 days, respectively.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer

Bob T. Li et al.

Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

F. Lordick et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Perspectives of HER2-targeting in gastric and esophageal cancer

James N. Gerson et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)

Add to Collection

Article Oncology

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Yusuke Ogitani et al.

CANCER SCIENCE (2016)

Add to Collection

Article Oncology

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Review Oncology

HER2 aberrations in cancer: Implications for therapy

Min Yan et al.

CANCER TREATMENT REVIEWS (2014)

Add to Collection

Article Pathology

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population

Ling Shan et al.

DIAGNOSTIC PATHOLOGY (2013)

Add to Collection

Article Pathology

Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas

Eun Yoon Cho et al.

MODERN PATHOLOGY (2013)

Add to Collection

Article Oncology

Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

Harry H. Yoon et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

Article Oncology

Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays

Kab Choong Kim et al.

ANNALS OF SURGICAL ONCOLOGY (2011)

Add to Collection

Review Biochemistry & Molecular Biology

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

M. M. Moasser

ONCOGENE (2007)

Add to Collection

Article Gastroenterology & Hepatology

HER-2/neu amplification is an independent prognostic factor in gastric cancer

Dong Il Park et al.

DIGESTIVE DISEASES AND SCIENCES (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.